Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**IO-VAC** is an individualized autologous dendritic-cell cancer vaccine developed and manufactured by IOZK. It is prepared from patient-derived monocytes differentiated into dendritic cells and loaded with antigens from the patient's own tumor-cell lysate together with immunostimulatory danger signals derived from Newcastle disease virus. The administered dendritic cells present tumor-associated antigens to the immune system, aiming to activate tumor-reactive T cells and establish antitumor immune memory. IO-VAC is used within IOZK's personalized multimodal immunotherapy approach for cancer and is not described by IOZK as a standard approved oncology treatment. ([iozk.de](https://www.iozk.de/en/the-iozk-immunotherapy/io-vac-vaccine/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IO-VAC.